Elite Pharmaceuticals Reports Positive Topline Results from a Pivotal Bioequivalence Study
14. August 2018 07:48 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP) a specialty pharmaceutical company developing abuse-deterrent opioids and...
Elite Pharmaceuticals Granted New Patent for Abuse Deterrent Technology
31. Mai 2017 07:30 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., May 31, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) announced today the issuance of European Patent No. 1615623 titled...
Elite Pharmaceuticals’ SequestOx™ Study Results Expected in July
25. Mai 2017 07:00 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., May 25, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP), today announced that top-line results for its reformulated SequestOx™ study are...
Elite Pharmaceuticals, Inc. to Host Conference Call to Discuss 3rd Quarter 2017 Financial Results on February 13, 2017
07. Februar 2017 08:00 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Feb. 07, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCQB:ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent...
Elite Announces U.S. FDA Priority Review Designation for SequestOx™ NDA
17. März 2016 07:00 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., March 17, 2016 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) today announced that the New Drug Application (NDA) for SequestOXTM...
Elite Pharmaceuticals, Inc. Reports Strong Growth for Second Quarter of Fiscal Year 2016
09. November 2015 16:37 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Nov. 09, 2015 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP), announced results for the quarter ended September 30, 2015, the second...
Elite Pharmaceuticals, Inc. to Host Conference Call and Webcast to Discuss 1st Quarter 2016 Financial Results on August 11, 2015
06. August 2015 08:00 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Aug. 6, 2015 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent...
Elite Pharmaceuticals Granted New Patent for Abuse Deterrent Technology
16. Juni 2015 10:33 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., June 16, 2015 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) announced today the issuance of U.S. Patent No. 9,056,054 entitled...
Elite Pharmaceuticals Granted New Patent for Abuse Deterrent Technology
22. April 2014 07:41 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., April 22, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) announced today the issuance of U.S. Patent No. 8,703,186 titled...
Elite Pharmaceuticals Expands Abuse Deterrent Technology Patent Portfolio Internationally
10. März 2014 07:46 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., March 10, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced the expansion of intellectual property protection surrounding...